NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, appointed Ronald A. Martell as president, CEO and a member of the board, according to a news release.
Mr. Martell previously served as CEO at Poniard Pharmaceuticals. Earlier, he worked at Imclone Systems, where he led the launch and initial commercialization of oncology drug Erbitux. Mr. Martell has also worked at Genentech, where he led the commercial launch of cancer drugs Rituxan and Herceptin.
Related Articles on Pain Management:
5 Changes for Outpatient Anesthesia in 2012: Thoughts From Dr. Gilbert Drozdow
New Maryland Surgery Center to Include Pain Management
16 New Pain Management Facility Openings in 2011
Related Articles on Pain Management:
5 Changes for Outpatient Anesthesia in 2012: Thoughts From Dr. Gilbert Drozdow
New Maryland Surgery Center to Include Pain Management
16 New Pain Management Facility Openings in 2011